Participated · Equity · Aug 2021

Techcyte provides a unified, AI-powered digital pathology platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. The company partners with laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers to deliver its platform to labs and clinics globally. Techcyte's veterinary business is currently profitable, and the company expects its environmental and human segments to reach profitability by next year. It is led by CEO Ben Cahoon and is headquartered in Orem, Utah. Techcyte announced it will deploy the newly raised capital to execute strategic priorities and support its path to profitability. The articles do not disclose revenue, user counts, or prior funding amounts.

Led · Series A · May 2021

TellBio, founded in 2019 and based in Beverly, Massachusetts, develops a proprietary circulating tumor cell (CTC) technology (TellDx) and a complementary therapeutics platform (TellRx). TellDx is a microfluidic diagnostic solution designed to detect live CTCs from patient liquid biopsies and is described as revenue-generating. TellRx is an early-stage therapeutics platform focused on generating anti-cancer medicines that specifically target CTCs. The company’s CTC approach and technology are exclusively licensed from Massachusetts General Hospital and originate from decades of academic and clinical research by its scientific founders. TellBio plans to use recent financing to further deploy TellDx globally and to advance TellRx programs in early-stage development. Strategic agreements announced concurrently — an exclusive TellDx license to Genetron for greater China and deployment at ARUP Laboratories in the U.S. — are intended to accelerate global commercialization and research adoption.

Participated · Series B · Oct 2019

PierianDx builds assay-agnostic interpretation technology and services to help providers, laboratories, and medical centers run next-generation sequencing (NGS) testing on site. The company pairs advanced interpretation software with a comprehensive genomic knowledgebase to empower clinicians to understand genetic variation and inform treatment decisions. PierianDx partners with industry leaders and medical facilities worldwide as they build or expand precision medicine programs. The firm was founded in 2014 as a technology-transfer spinout from Washington University in St. Louis and is headquartered in St. Louis. Management says the business is expanding commercially as more healthcare organizations seek to internalize NGS testing capabilities. The recent financing is intended to fund commercial expansion and continued product and team development to bring genomics into more clinical settings. PierianDx offers a SaaS clinical genomics informatics platform that enables the practice of clinical next-generation sequencing (NGS) as a standard of care and supports advanced molecular diagnostic laboratories. The company also operates a CAP- and CLIA-accredited laboratory and provides integrated reporting and decision-support across the clinical care spectrum. PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Leadership emphasizes adding clinical expertise and resources to drive adoption of clinical NGS globally. Management plans to accelerate commercial expansion across the U.S. and international markets including Europe, Asia, Australia, and Latin America. PierianDx was founded in 2014 out of Washington University in St. Louis. PierianDx provides genomic software and services to enable data-driven personalized medicine. Its flagship platform, Clinical Genomicist Workstation (CGW), delivers data-driven workflows for health systems, academic medical centers, and commercial labs to support genomic analysis, interpretation and reporting. Led by CEO Ted Briscoe, the company focuses on improving patient outcomes through precise genomic analysis. PierianDx said it will use the new funding to accelerate product development and expand sales, marketing and operations. The company raised $9.25M in a Series A to support these initiatives.

Participated · Series A · Sep 2016

IDbyDNA develops the Explify software platform, a metagenomics technology that detects, identifies, and interprets microorganisms and their role in human health. The Explify platform identifies more than 50,000 microorganisms and over 3,000 known common and rare pathogens, and includes quantification and antimicrobial resistance (AMR) detection. Explify offers secure data privacy, highly curated and well‑annotated databases, rapid metagenomic analysis, QA/QC applications, custom user interfaces, and automated report generation. The company announced a $20 million Series B to fuel growth of Explify into the worldwide infectious disease and microbiome testing markets and to advance customer adoption via partnerships and newly signed contracts with commercial labs, hospitals, and academic institutions. Proceeds will also support opening a CLIA‑approved commercial laboratory at IDbyDNA’s Salt Lake City facility to enable end‑to‑end clinical microbial profiling, syndromic testing, and next‑generation sequencing. The company operates in San Francisco and Salt Lake City. IDbyDNA develops metagenomics-based technologies—notably the Taxonomer DNA search platform—to enable universal microorganism detection via next‑generation sequencing. The company’s core product, Taxonomer, is intended to let clinicians and scientists detect any pathogen in any sample, easing adoption of metagenomics in clinical settings. IDbyDNA plans to further develop its Taxonomer-based DNA search technologies and to launch metagenomics-based clinical tests for infectious diseases. The company says Taxonomer.com was launched in May 2106 and already has registered users from more than 150 academic or government institutions and corporations. Financially, IDbyDNA closed a $9m Series A to support product development and clinical test rollouts. The company was founded in November 2014 by Guochun Liao, Robert Schlaberg, Mark Yandell and Martin Reese.